Ted R. Mannen is a Strategic Advisor for EBG Advisors, Inc. He has broad experience, including  serving as a lawyer and staff member in Congress; as General Counsel and as a senior policy, reimbursement, and public affairs executive at the international device and diagnostics trade group now known as the Advanced Medical Technology Association; and as Partner in two law firms and President of two law firm consulting affiliates.

Representative Experience

Health  Regulation & Intelligence

Mr. Mannen represents life sciences companies and trade associations on third-party payer regulatory issues and addresses these issues as part of due-diligence evaluations for investor organizations. Mr. Mannen developed an intelligence platform that evaluates government and other primary-information sources.

Health Policy & Legislation

For device, diagnostics, and pharmaceutical companies and trade associations, Mr. Mannen provides policy counseling and drafts and interprets legislation, amendments, specifications, and related materials. He has worked on health reform, Medicare, Medicaid, FDA, AHRQ, and other federal and state statutes and legislation.

Mr. Mannen previously served as an attorney in the U.S. House’s Office of the Legislative Counsel, where he drafted legislation for the Judiciary Committee. He was later an aide to U.S. Senator Adlai E. Stevenson (IL) on Banking Committee matters. Mr. Mannen has testified before Congressional committees on a number of life sciences issues. The American Bar Association Journal, in reference to Mr. Mannen’s legislative drafting, described him as one of a “new breed of lawyer-lobbyist” that offers Congress “sophistication and expertise.”

Market Access & Reimbursement

Mr. Mannen’s broad experience in this area includes:

  • Helping life sciences companies introduce their innovations into reimbursed markets, such as in Medicare and private health plans
  • Advising clients on how technology adoption is influenced by third-party insurer coverage, coding, and payment policies, as well as by emerging incentives designed to reward accountable, high-value care
  • Building and leading interdisciplinary teams to develop reimbursement assessments, strategies, and plans for companies in a variety of service categories, including home drug delivery; imaging; cardiovascular, orthopedic, and other implants; DME; laboratory tests; and screening, remote-monitoring, and other types of new medical technologies (many of which are commercialized in the United States as medical devices)


  • Northwestern University Pritzker School of Law  (J.D., cum laude)